For the 26 patients with salivary gland tumor treated with PBSPT, at a median follow-up time of 46 months, 5 (19%), 2 (8%), 3 (12%) and 2 (8%) patients presented with distant, local, locoregional failures and death, respectively. The estimated 4-year OS and LC were 90% and 90%. Local regional control and distant control were 87 and 77%. Grade 3 late toxicity was observed in 2 (8%) patients. The estimated 4 year late high-grade (≥3) toxicity-free survival was 78.4%.